Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck wins patent infringement suits against Mylan
The US District Court has ruled in favor of Merck in two jointly related patent infringement suits. Merck general counsel and executive vice president Bruce Kuhlik said, "The
The US District Court has ruled in favor of Merck in two jointly related patent infringement suits. Merck general counsel and executive vice president Bruce Kuhlik said, "The
Arzerra (ofatumumab) is submitted for the approval to treat chronic lymphocytic leukemia (CLL). Genmab chief executive officer Jan van de Winkel said, "This marks another important achievement in
The products include low particulate carboys and bottles, manufactured from resins approved for medical applications, to store and transport biopharmaceuticals, culture media, bulk vaccines and other biotech materials.
Cholestor supplement can keep cholesterol ratios in balance naturally, claims the company. VitalMax Vitamins medical expert Mark Rosenberg said Cholestor helps put HDL and LDL into perfect ratio
Vyvanse is a prescription medicine currently approved in the US and Canada, as well as in Brazil under the name Venvanse, for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
The blinded, ascending, single dose study demonstrated that RG3039 was well tolerated at all doses administered and showed evidence of a dose-related drug response resulting in 90% inhibition
The study showed that levomilnacipran considerably reduced depression symptoms in MDD patients compared to placebo and further analyses of the data are ongoing. The companies expect to file
Hi-Tech is in the process of launching Lidocaine 5% Ointment, indicated for use as a local anesthetic, and the profits from the sale of the product will be
Alogliptin is a DPP-4 inhibitor that is being investigated in the US, as an adjunct to diet and exercise, for the treatment of type 2 diabetes. The FDA
The open-label Phase II clinical trial will evaluate the preliminary efficacy and safety of INNO-206 in pancreatic cancer. The patients enrolled in the trial will be treated with